Conference on Generics 2009

Feb. 9, 2009 - PRLog -- Conference on Generics 2009
To be held at 21st - 22nd April 2009, BSG Conference Centre, London, UK

In the last ten years - from 1998 to 2008 - the branded pharmaceuticals industry has been extremely successful at producing drugs with high effectiveness and a high volume of sales

As the ageing population increases, then so will drug sales, particularly for modern medicines to treat chronic conditions, including CNS (Parkinson's, Alzheimer's) and cardiovascular disorders - especially statins and antihypertensive drugs. The shift by healthcare providers from more expensive branded medicines to cheaper generic drugs will remain a significant driver in this market. Increasing use of generic medicines globally, will help governments improve their provision of wider and better healthcare options. Principally, the demographic shift in population in the growing pharmaceutical markets, coupled with rising healthcare costs will be the major driver for growth of the global generic pharmaceutical market. Providing significant revenue opportunities for both foreign and domestic companies.

Recent years have witnessed a large number of merger and acquisition (M&A) activity within the generic pharmaceutical industry. High profile deals highlight this trend and emphasise how rapid expansion is encouraged in such a successful market. All of the leading generic companies have been involved in some M&A activity in order to gain advantage over their competitors. Initiating mergers and acquisitions can provide significant advantages, either by gaining access to a rapidly growing market, such as those in Central and Eastern Europe, or by enhancing a company's production capabilities.

The generic drugs market in the US is the most established in the world. It is also a good example of how the introduction of appropriate legislation can be used to encourage the use of generic drugs and stimulate the generic drugs industry. The introduction of the Hatch-Waxman Act has had a radical effect on the generic pharmaceuticals market in the US. However, the effect on growth is now limited as the branded pharmaceutical industry has become more proficient at coping with generic erosion.

Competition within the generics market is becoming increasingly fierce with ever more companies entering the market. Generics manufacturers need to be aware of which branded products and formulations to target in order to receive the greatest return on investment. From 2008-2010 a total of 36 key drugs are expected to lose patent protection.

The objective of this conference is to bring together the different industry players who compete in the same market arena but from considerably disparate outlooks on marketing and product development. For the leading pharmaceutical companies to be aware of and understand their market opponents’ strategies and rationale makes for a substantial competitive edge in the long-term. Generics are attracting a huge amount of interest around the world with leading generic companies being highly effective orgainsations. Visiongain's conference will shed light on all aspects of the generic industry.

Reasons to attend:
• Situation Check - Identify the key players in generic company merger and acquisition activity - How this will effect the generic industry?
• The current legal patent/IP framework - How did we get to the situation we are at now? Perspectives on generics legal challenges
• Take part in our panel discussions - Regulatory developments impacting on generic medicine companies. Techniques, tactics and the struggle for market share
• Examine the USA - Regulatory, Policy, Clinical Consideration and Implications of Biosimilars.
• Expand your Global reach and look at strategies within the Europe, the Middle East, America and Asia Generic Market. How do they compare and evolve in the lessons being taught.
• Engage with a very distinguished audience that will enhance your reputation as a key player in the revolutionising market of generics

Who Should Attend?
Generic Pharmaceutical Companies, Drug Regulators, Healthcare Agencies, Government Departments, Contract Research/Biomanufacturing Organisations, Regulatory Affairs, Academics, Consultants, Legal Experts, Analysis
VPs, Directors, Heads, Managers of:
• New Product Development
• Lifecycle Management
• Regulatory Compliance
• Drug Safety & Risk Management
• Quality Affairs/ Quality Control
• Consultants
• API Maufactures
• Process Science
• Business Development
• Business Operations
• Scientific Affairs
• Commercial Affairs
• Marketing
• Analytical Characterisation
• Process Control and Analytical Technologies
• Clinical Immunology
• Biopharmaceuticals/ Biotherapeutics
• Principal Scientist
• Chief Scientific Officer

For more information kindly visit: http://www.bharatbook.com/seminars/Conference-on-Generics...

OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438  
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com